USFDA inspects two units of Aurobindo Pharma; makes observations

Published On 2016-02-02 02:53 GMT   |   Update On 2016-02-02 02:53 GMT

New Delhi: Aurobindo Pharma said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one unit."The said facilities underwent pre-approval inspection by the United States Food and Drug Administration (USFDA) and there was no Form 483 issued to unit III. With regard to unit VII, there were certain observations," Aurobindo Pharma said in...

Login or Register to read the full article
New Delhi: Aurobindo Pharma said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one unit.

"The said facilities underwent pre-approval inspection by the United States Food and Drug Administration (USFDA) and there was no Form 483 issued to unit III. With regard to unit VII, there were certain observations," Aurobindo Pharma said in a filing to BSE.

The company however did not provide any details about the observations made by FDA.

"The company is appropriately responding and this has no perceived impact on operations and exports from the said facility," it added.

The company's unit III facility is a multi-product oral dosage form facility while unit VII formulations facility in Hyderabad manufactures oral non-antibiotic products.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News